Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma

Trial Profile

A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GZ 17-6.02 (Primary) ; Capecitabine
  • Indications Breast cancer; Colorectal cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms GEN602
  • Sponsors Genzada Pharmaceuticals

Most Recent Events

  • 22 Dec 2022 Status changed from recruiting to active, no longer recruiting.
  • 11 May 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 44 to 127, treatment arm changed from 1 to 3. Official title also changed.
  • 11 May 2022 Planned number of patients changed from 44 to 127.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top